Date: 2014-09-29
Type of information: Services contract
Compound: EndoPAT™ devices and accessories for endothelial function assessment
Company: Galmed Pharmaceuticals (Israel) Itamar Medical (USA - MA)
Therapeutic area: Hepatic diseases - Liver diseases - Metabolic diseases
Type agreement: services
Action mechanism:
Disease:
Details: * On September 29, 2014, Galmed Pharmaceuticals , a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical, a publicly-traded medical device company whose technology has been cleared by the FDA, for endothelial, or arterial, function assessment, which is a novel risk marker for cardiovascular disease. Galmed intends to use Itamar Medical\'s EndoPAT technology to include an assessment of endothelial function in its planned Phase IIb clinical trial of its drug candidate, aramchol, involving 240 Non-Alcoholic Steato-Hepatitis, or NASH, patients suffering from obesity and insulin resistance. As Galmed previously disclosed, this Phase IIb clinical trial is expected to begin later this year and involve medical centers within the European Union, Israel and Latin America. According to scientific literature, NASH patients are at risk of developing cardiovascular complications and severe liver complications, such as cirrhosis of the liver and liver cancer.
Financial terms:
Latest news:
